A clinical trial involving insulin lispro reached completed status as of October 6, 2026. The study, titled "A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)," is registered under identifier NCT06280703.
The trial was conducted in Phase 1 and enrolled both healthy participants and participants with Type 1 Diabetes Mellitus. According to the registry listing, the current status of the study is COMPLETED.
No results, efficacy data, or safety findings were included in this update. The listing reflects only the study title, phase, and completion status as recorded. Insulin lispro remains an approved compound, and this trial update does not by itself indicate any change to that regulatory status.
Readers interested in further detail on the study design or its registered endpoints can consult the original clinical trial listing directly. For more background on insulin lispro generally, readers can refer to the compound overview page.